{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-22-006665","form_type":"8-K","ticker":"PHIO","cik":"0001533040","company_name":"Phio Pharmaceuticals Corp.","filed_at":"2022-09-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.058109+00:00","generated_at":"2026-06-23T06:41:39.480982+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Phio Pharmaceuticals appoints Robert Bitterman as interim Executive Chairman, effective Sept. 26, 2022","bullets":["Robert Bitterman, Board Chairman since 2012, named interim Executive Chairman and principal executive/financial officer.","Bitterman receives $175,000 annual base salary (incl. $55,000 Board fee) and 40,000 RSUs vesting Oct. 1, 2023.","Dr. Geert Cauwenbergh ceases as interim principal executive/financial officer and resumes independent Board role.","Robert Ferrara appointed Lead Independent Director; he chairs the Audit Committee and is a CPA.","Press release issued Sept. 29, 2022, announcing the leadership changes."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-22-006665","json":"https://secwatch.observer/filing/0001683168-22-006665.json","markdown":"https://secwatch.observer/filing/0001683168-22-006665.md","text":"https://secwatch.observer/filing/0001683168-22-006665.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533040/000168316822006665/0001683168-22-006665-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533040/000168316822006665/phio_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T06:41:39.480982+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"67c283527f","claim":"Geert Cauwenbergh changed role as Independent Director at Phio Pharmaceuticals Corp..","evidence_excerpt":"Dr. Geert Cauwenbergh, a member of the Company’s Board, will no longer serve as the Company’s interim principal executive officer and interim principal financial officer, which positions he held since May 4, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533040/000168316822006665/0001683168-22-006665-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving as interim PEO/PFO and resumed independent director role"},{"label":"Role","value":"Independent Director"}],"fact_type":"executive_change"},{"claim_id":"96a17225f4","claim":"Robert J. Bitterman was appointed as Interim Executive Chairman at Phio Pharmaceuticals Corp..","evidence_excerpt":"approved the appointment of Robert J. Bitterman, Chairman of the Company’s Board, to serve as the Company’s interim Executive Chairman, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533040/000168316822006665/0001683168-22-006665-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Executive Chairman"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}